Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats
We attempted to elucidate the contribution of complement to allergic asthma. Rat sensitized to OVA received repeated intratracheal exposures to OVA for up to 3 consecutive days, and pulmonary resistance was then estimated for up to 6 h after the last exposure. Whereas the immediate airway response (...
Gespeichert in:
Veröffentlicht in: | The Journal of immunology (1950) 2001-10, Vol.167 (8), p.4651-4660 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4660 |
---|---|
container_issue | 8 |
container_start_page | 4651 |
container_title | The Journal of immunology (1950) |
container_volume | 167 |
creator | Abe, Masayoshi Shibata, Kazuhiko Akatsu, Hiroyasu Shimizu, Naomi Sakata, Noriyuki Katsuragi, Takeshi Okada, Hidechika |
description | We attempted to elucidate the contribution of complement to allergic asthma. Rat sensitized to OVA received repeated intratracheal exposures to OVA for up to 3 consecutive days, and pulmonary resistance was then estimated for up to 6 h after the last exposure. Whereas the immediate airway response (IAR) in terms of R(L) tended to decrease in proportion to the number of OVA exposures, late airway response (LAR) became prominent only after three. Although premedication with two kinds of complement inhibitors, soluble complement receptor type 1 (sCR1) or nafamostat mesylate, resulted in inhibition of the IAR after either a single or a double exposure, the LAR was inhibited after the triple. Premedication with a C5a receptor antagonist (C5aRA) before every exposure to OVA also inhibited the LAR after three. Repeated OVA exposure resulted in eosinophil and neutrophil infiltration into the bronchial submucosa which was suppressed by premedication with sCR1 or C5aRA. Up-regulation of C5aR mRNA was shown in lungs after triple OVA exposure, but almost no up-regulation of C3aR. Pretreatment with sCR1 or C5aRA suppressed the up-regulation of C5aR expression as well as cytokine messages in the lungs. The suppression of LAR by pretreatment with sCR1 was reversed by intratracheal instillation of rat C5a desArg the action of which was inhibited by C5aRA. In contrast, rat C3a desArg or cytokine-induced neutrophil chemoattractant-1 induced cellular infiltration into the bronchial submucosa by costimulation with OVA, but these had no influence on the LAR. These differences might be explained by the fact that costimulation with OVA and C5a synergistically potentiated IAR, whereas that with OVA and either C3a or cytokine-induced neutrophil chemoattractant-1 did not. C5a generated by Ag-Ab complexes helps in the production of cytokines and contributes to the LAR after repeated exposure to Ag. |
doi_str_mv | 10.4049/jimmunol.167.8.4651 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72180467</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18116836</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-aa0e594ea2108b32cae22036630cfa99cf58a5215b1127a035eaca3d3a864d293</originalsourceid><addsrcrecordid>eNqFkc2O0zAURi0EYsrAEyAhr2CV4p_YSZZRNcMgVUIawdq6TW9ajxw72I4yfXtStSPYsbKufL6zOYR85GxdsrL5-mSHYfLBrbmu1vW61Iq_IiuuFCu0Zvo1WTEmRMErXd2Qdyk9McY0E-VbcsO5anjVqBXxm-BztLsp2-Bp6GnrYTyeHOTwbD3dKKA50C1kpK2NM5zoI6Yx-ISJtn3GuNwjLt97evc8hjRFvFiyPaA_b1vnMB5sRx8hp_fkTQ8u4Yfre0t-3d_93DwU2x_fvm_abdGVlcoFAEPVlAiCs3onRQcoBJNaS9b10DRdr2pQgqsd56ICJhVCB3IvodblXjTylny-eMcYfk-Yshls6tA58BimZCrBa1bq6r8grznXtdQLKC9gF0NKEXszRjtAPBnOzLmHeelhlh6mNucey-rTVT_tBtz_3VwDLMCXC3C0h-NsI5o0gHMLzs08z_-o_gCaJZbS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18116836</pqid></control><display><type>article</type><title>Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Abe, Masayoshi ; Shibata, Kazuhiko ; Akatsu, Hiroyasu ; Shimizu, Naomi ; Sakata, Noriyuki ; Katsuragi, Takeshi ; Okada, Hidechika</creator><creatorcontrib>Abe, Masayoshi ; Shibata, Kazuhiko ; Akatsu, Hiroyasu ; Shimizu, Naomi ; Sakata, Noriyuki ; Katsuragi, Takeshi ; Okada, Hidechika</creatorcontrib><description>We attempted to elucidate the contribution of complement to allergic asthma. Rat sensitized to OVA received repeated intratracheal exposures to OVA for up to 3 consecutive days, and pulmonary resistance was then estimated for up to 6 h after the last exposure. Whereas the immediate airway response (IAR) in terms of R(L) tended to decrease in proportion to the number of OVA exposures, late airway response (LAR) became prominent only after three. Although premedication with two kinds of complement inhibitors, soluble complement receptor type 1 (sCR1) or nafamostat mesylate, resulted in inhibition of the IAR after either a single or a double exposure, the LAR was inhibited after the triple. Premedication with a C5a receptor antagonist (C5aRA) before every exposure to OVA also inhibited the LAR after three. Repeated OVA exposure resulted in eosinophil and neutrophil infiltration into the bronchial submucosa which was suppressed by premedication with sCR1 or C5aRA. Up-regulation of C5aR mRNA was shown in lungs after triple OVA exposure, but almost no up-regulation of C3aR. Pretreatment with sCR1 or C5aRA suppressed the up-regulation of C5aR expression as well as cytokine messages in the lungs. The suppression of LAR by pretreatment with sCR1 was reversed by intratracheal instillation of rat C5a desArg the action of which was inhibited by C5aRA. In contrast, rat C3a desArg or cytokine-induced neutrophil chemoattractant-1 induced cellular infiltration into the bronchial submucosa by costimulation with OVA, but these had no influence on the LAR. These differences might be explained by the fact that costimulation with OVA and C5a synergistically potentiated IAR, whereas that with OVA and either C3a or cytokine-induced neutrophil chemoattractant-1 did not. C5a generated by Ag-Ab complexes helps in the production of cytokines and contributes to the LAR after repeated exposure to Ag.</description><identifier>ISSN: 0022-1767</identifier><identifier>EISSN: 1550-6606</identifier><identifier>DOI: 10.4049/jimmunol.167.8.4651</identifier><identifier>PMID: 11591795</identifier><language>eng</language><publisher>United States: Am Assoc Immnol</publisher><subject><![CDATA[Airway Resistance ; Anaphylatoxin C5a ; Animals ; Antigens - administration & dosage ; Antigens - immunology ; Antigens, CD - genetics ; Antigens, CD - isolation & purification ; Asthma - drug therapy ; Asthma - etiology ; Asthma - immunology ; Bronchi - pathology ; Bronchoalveolar Lavage Fluid - cytology ; Chemokine CCL11 ; Chemokines, CC ; Chemokines, CXC ; Chemotactic Factors ; Complement C3a - analogs & derivatives ; Complement C3a - pharmacology ; Complement C5a - immunology ; Complement C5a, des-Arginine - pharmacology ; complement receptor 1 ; Cytokines - genetics ; Cytokines - isolation & purification ; Growth Substances ; Guanidines - therapeutic use ; Hypersensitivity - drug therapy ; Hypersensitivity - etiology ; Hypersensitivity - immunology ; Intercellular Signaling Peptides and Proteins ; Lung - immunology ; Membrane Proteins ; Ovalbumin - administration & dosage ; Ovalbumin - immunology ; Rats ; Receptor, Anaphylatoxin C5a ; Receptors, Complement - genetics ; Receptors, Complement - isolation & purification ; Receptors, Complement 3b - therapeutic use ; RNA, Messenger - isolation & purification]]></subject><ispartof>The Journal of immunology (1950), 2001-10, Vol.167 (8), p.4651-4660</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-aa0e594ea2108b32cae22036630cfa99cf58a5215b1127a035eaca3d3a864d293</citedby><cites>FETCH-LOGICAL-c475t-aa0e594ea2108b32cae22036630cfa99cf58a5215b1127a035eaca3d3a864d293</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11591795$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abe, Masayoshi</creatorcontrib><creatorcontrib>Shibata, Kazuhiko</creatorcontrib><creatorcontrib>Akatsu, Hiroyasu</creatorcontrib><creatorcontrib>Shimizu, Naomi</creatorcontrib><creatorcontrib>Sakata, Noriyuki</creatorcontrib><creatorcontrib>Katsuragi, Takeshi</creatorcontrib><creatorcontrib>Okada, Hidechika</creatorcontrib><title>Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats</title><title>The Journal of immunology (1950)</title><addtitle>J Immunol</addtitle><description>We attempted to elucidate the contribution of complement to allergic asthma. Rat sensitized to OVA received repeated intratracheal exposures to OVA for up to 3 consecutive days, and pulmonary resistance was then estimated for up to 6 h after the last exposure. Whereas the immediate airway response (IAR) in terms of R(L) tended to decrease in proportion to the number of OVA exposures, late airway response (LAR) became prominent only after three. Although premedication with two kinds of complement inhibitors, soluble complement receptor type 1 (sCR1) or nafamostat mesylate, resulted in inhibition of the IAR after either a single or a double exposure, the LAR was inhibited after the triple. Premedication with a C5a receptor antagonist (C5aRA) before every exposure to OVA also inhibited the LAR after three. Repeated OVA exposure resulted in eosinophil and neutrophil infiltration into the bronchial submucosa which was suppressed by premedication with sCR1 or C5aRA. Up-regulation of C5aR mRNA was shown in lungs after triple OVA exposure, but almost no up-regulation of C3aR. Pretreatment with sCR1 or C5aRA suppressed the up-regulation of C5aR expression as well as cytokine messages in the lungs. The suppression of LAR by pretreatment with sCR1 was reversed by intratracheal instillation of rat C5a desArg the action of which was inhibited by C5aRA. In contrast, rat C3a desArg or cytokine-induced neutrophil chemoattractant-1 induced cellular infiltration into the bronchial submucosa by costimulation with OVA, but these had no influence on the LAR. These differences might be explained by the fact that costimulation with OVA and C5a synergistically potentiated IAR, whereas that with OVA and either C3a or cytokine-induced neutrophil chemoattractant-1 did not. C5a generated by Ag-Ab complexes helps in the production of cytokines and contributes to the LAR after repeated exposure to Ag.</description><subject>Airway Resistance</subject><subject>Anaphylatoxin C5a</subject><subject>Animals</subject><subject>Antigens - administration & dosage</subject><subject>Antigens - immunology</subject><subject>Antigens, CD - genetics</subject><subject>Antigens, CD - isolation & purification</subject><subject>Asthma - drug therapy</subject><subject>Asthma - etiology</subject><subject>Asthma - immunology</subject><subject>Bronchi - pathology</subject><subject>Bronchoalveolar Lavage Fluid - cytology</subject><subject>Chemokine CCL11</subject><subject>Chemokines, CC</subject><subject>Chemokines, CXC</subject><subject>Chemotactic Factors</subject><subject>Complement C3a - analogs & derivatives</subject><subject>Complement C3a - pharmacology</subject><subject>Complement C5a - immunology</subject><subject>Complement C5a, des-Arginine - pharmacology</subject><subject>complement receptor 1</subject><subject>Cytokines - genetics</subject><subject>Cytokines - isolation & purification</subject><subject>Growth Substances</subject><subject>Guanidines - therapeutic use</subject><subject>Hypersensitivity - drug therapy</subject><subject>Hypersensitivity - etiology</subject><subject>Hypersensitivity - immunology</subject><subject>Intercellular Signaling Peptides and Proteins</subject><subject>Lung - immunology</subject><subject>Membrane Proteins</subject><subject>Ovalbumin - administration & dosage</subject><subject>Ovalbumin - immunology</subject><subject>Rats</subject><subject>Receptor, Anaphylatoxin C5a</subject><subject>Receptors, Complement - genetics</subject><subject>Receptors, Complement - isolation & purification</subject><subject>Receptors, Complement 3b - therapeutic use</subject><subject>RNA, Messenger - isolation & purification</subject><issn>0022-1767</issn><issn>1550-6606</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2O0zAURi0EYsrAEyAhr2CV4p_YSZZRNcMgVUIawdq6TW9ajxw72I4yfXtStSPYsbKufL6zOYR85GxdsrL5-mSHYfLBrbmu1vW61Iq_IiuuFCu0Zvo1WTEmRMErXd2Qdyk9McY0E-VbcsO5anjVqBXxm-BztLsp2-Bp6GnrYTyeHOTwbD3dKKA50C1kpK2NM5zoI6Yx-ISJtn3GuNwjLt97evc8hjRFvFiyPaA_b1vnMB5sRx8hp_fkTQ8u4Yfre0t-3d_93DwU2x_fvm_abdGVlcoFAEPVlAiCs3onRQcoBJNaS9b10DRdr2pQgqsd56ICJhVCB3IvodblXjTylny-eMcYfk-Yshls6tA58BimZCrBa1bq6r8grznXtdQLKC9gF0NKEXszRjtAPBnOzLmHeelhlh6mNucey-rTVT_tBtz_3VwDLMCXC3C0h-NsI5o0gHMLzs08z_-o_gCaJZbS</recordid><startdate>20011015</startdate><enddate>20011015</enddate><creator>Abe, Masayoshi</creator><creator>Shibata, Kazuhiko</creator><creator>Akatsu, Hiroyasu</creator><creator>Shimizu, Naomi</creator><creator>Sakata, Noriyuki</creator><creator>Katsuragi, Takeshi</creator><creator>Okada, Hidechika</creator><general>Am Assoc Immnol</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20011015</creationdate><title>Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats</title><author>Abe, Masayoshi ; Shibata, Kazuhiko ; Akatsu, Hiroyasu ; Shimizu, Naomi ; Sakata, Noriyuki ; Katsuragi, Takeshi ; Okada, Hidechika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-aa0e594ea2108b32cae22036630cfa99cf58a5215b1127a035eaca3d3a864d293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Airway Resistance</topic><topic>Anaphylatoxin C5a</topic><topic>Animals</topic><topic>Antigens - administration & dosage</topic><topic>Antigens - immunology</topic><topic>Antigens, CD - genetics</topic><topic>Antigens, CD - isolation & purification</topic><topic>Asthma - drug therapy</topic><topic>Asthma - etiology</topic><topic>Asthma - immunology</topic><topic>Bronchi - pathology</topic><topic>Bronchoalveolar Lavage Fluid - cytology</topic><topic>Chemokine CCL11</topic><topic>Chemokines, CC</topic><topic>Chemokines, CXC</topic><topic>Chemotactic Factors</topic><topic>Complement C3a - analogs & derivatives</topic><topic>Complement C3a - pharmacology</topic><topic>Complement C5a - immunology</topic><topic>Complement C5a, des-Arginine - pharmacology</topic><topic>complement receptor 1</topic><topic>Cytokines - genetics</topic><topic>Cytokines - isolation & purification</topic><topic>Growth Substances</topic><topic>Guanidines - therapeutic use</topic><topic>Hypersensitivity - drug therapy</topic><topic>Hypersensitivity - etiology</topic><topic>Hypersensitivity - immunology</topic><topic>Intercellular Signaling Peptides and Proteins</topic><topic>Lung - immunology</topic><topic>Membrane Proteins</topic><topic>Ovalbumin - administration & dosage</topic><topic>Ovalbumin - immunology</topic><topic>Rats</topic><topic>Receptor, Anaphylatoxin C5a</topic><topic>Receptors, Complement - genetics</topic><topic>Receptors, Complement - isolation & purification</topic><topic>Receptors, Complement 3b - therapeutic use</topic><topic>RNA, Messenger - isolation & purification</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abe, Masayoshi</creatorcontrib><creatorcontrib>Shibata, Kazuhiko</creatorcontrib><creatorcontrib>Akatsu, Hiroyasu</creatorcontrib><creatorcontrib>Shimizu, Naomi</creatorcontrib><creatorcontrib>Sakata, Noriyuki</creatorcontrib><creatorcontrib>Katsuragi, Takeshi</creatorcontrib><creatorcontrib>Okada, Hidechika</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of immunology (1950)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abe, Masayoshi</au><au>Shibata, Kazuhiko</au><au>Akatsu, Hiroyasu</au><au>Shimizu, Naomi</au><au>Sakata, Noriyuki</au><au>Katsuragi, Takeshi</au><au>Okada, Hidechika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats</atitle><jtitle>The Journal of immunology (1950)</jtitle><addtitle>J Immunol</addtitle><date>2001-10-15</date><risdate>2001</risdate><volume>167</volume><issue>8</issue><spage>4651</spage><epage>4660</epage><pages>4651-4660</pages><issn>0022-1767</issn><eissn>1550-6606</eissn><abstract>We attempted to elucidate the contribution of complement to allergic asthma. Rat sensitized to OVA received repeated intratracheal exposures to OVA for up to 3 consecutive days, and pulmonary resistance was then estimated for up to 6 h after the last exposure. Whereas the immediate airway response (IAR) in terms of R(L) tended to decrease in proportion to the number of OVA exposures, late airway response (LAR) became prominent only after three. Although premedication with two kinds of complement inhibitors, soluble complement receptor type 1 (sCR1) or nafamostat mesylate, resulted in inhibition of the IAR after either a single or a double exposure, the LAR was inhibited after the triple. Premedication with a C5a receptor antagonist (C5aRA) before every exposure to OVA also inhibited the LAR after three. Repeated OVA exposure resulted in eosinophil and neutrophil infiltration into the bronchial submucosa which was suppressed by premedication with sCR1 or C5aRA. Up-regulation of C5aR mRNA was shown in lungs after triple OVA exposure, but almost no up-regulation of C3aR. Pretreatment with sCR1 or C5aRA suppressed the up-regulation of C5aR expression as well as cytokine messages in the lungs. The suppression of LAR by pretreatment with sCR1 was reversed by intratracheal instillation of rat C5a desArg the action of which was inhibited by C5aRA. In contrast, rat C3a desArg or cytokine-induced neutrophil chemoattractant-1 induced cellular infiltration into the bronchial submucosa by costimulation with OVA, but these had no influence on the LAR. These differences might be explained by the fact that costimulation with OVA and C5a synergistically potentiated IAR, whereas that with OVA and either C3a or cytokine-induced neutrophil chemoattractant-1 did not. C5a generated by Ag-Ab complexes helps in the production of cytokines and contributes to the LAR after repeated exposure to Ag.</abstract><cop>United States</cop><pub>Am Assoc Immnol</pub><pmid>11591795</pmid><doi>10.4049/jimmunol.167.8.4651</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-1767 |
ispartof | The Journal of immunology (1950), 2001-10, Vol.167 (8), p.4651-4660 |
issn | 0022-1767 1550-6606 |
language | eng |
recordid | cdi_proquest_miscellaneous_72180467 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Airway Resistance Anaphylatoxin C5a Animals Antigens - administration & dosage Antigens - immunology Antigens, CD - genetics Antigens, CD - isolation & purification Asthma - drug therapy Asthma - etiology Asthma - immunology Bronchi - pathology Bronchoalveolar Lavage Fluid - cytology Chemokine CCL11 Chemokines, CC Chemokines, CXC Chemotactic Factors Complement C3a - analogs & derivatives Complement C3a - pharmacology Complement C5a - immunology Complement C5a, des-Arginine - pharmacology complement receptor 1 Cytokines - genetics Cytokines - isolation & purification Growth Substances Guanidines - therapeutic use Hypersensitivity - drug therapy Hypersensitivity - etiology Hypersensitivity - immunology Intercellular Signaling Peptides and Proteins Lung - immunology Membrane Proteins Ovalbumin - administration & dosage Ovalbumin - immunology Rats Receptor, Anaphylatoxin C5a Receptors, Complement - genetics Receptors, Complement - isolation & purification Receptors, Complement 3b - therapeutic use RNA, Messenger - isolation & purification |
title | Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T10%3A54%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Contribution%20of%20Anaphylatoxin%20C5a%20to%20Late%20Airway%20Responses%20After%20Repeated%20Exposure%20of%20Antigen%20to%20Allergic%20Rats&rft.jtitle=The%20Journal%20of%20immunology%20(1950)&rft.au=Abe,%20Masayoshi&rft.date=2001-10-15&rft.volume=167&rft.issue=8&rft.spage=4651&rft.epage=4660&rft.pages=4651-4660&rft.issn=0022-1767&rft.eissn=1550-6606&rft_id=info:doi/10.4049/jimmunol.167.8.4651&rft_dat=%3Cproquest_cross%3E18116836%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18116836&rft_id=info:pmid/11591795&rfr_iscdi=true |